STAT

Opinion: Developing a new gene therapy was hard. So was figuring out how to get it to patients

After a career spent in pharmaceutical commercial strategy and operations, I thought I had a handle on what was needed to launch a new therapy. A new gene therapy taught…

After a career spent in pharmaceutical commercial strategy and operations, I thought I had a handle on what was required to launch a new therapy. But I’ve learned many lessons — and faced a few curveballs — in the 12 months since the FDA approved Luxturna (voretigene neparvovec), a one-time gene therapy for the treatment of patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

To bring this first-of-its-kind therapy to U.S. patients, Spark Therapeutics, where I serve as chief commercial officer, had

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readScience
To Sleep, Perchance To Forget? Scientists Pinpoint In Mice The Neurons That Control Memory While Dreaming
If you wonder why we forget our dreams, new research in mice might answer that question and others related to memory.
STAT4 min read
Opinion: Cokie Roberts: A Beacon For Cancer Survivors Like Me
In full view of her ABC News audience and on the air at NPR, Cokie Roberts lived publicly with breast cancer for 17 years. That's a victory, even if she…
STAT4 min readSociety
Opinion: Constant, Rapid Testing Is Key To Creating The ‘Learning Health System’ Of The Future
The view that health care systems of the future will be "learning health systems" is inspiring. Routine experimentation to identify what works and what doesn't is the way to make…